ELVN at a glance
Enliven Therapeutics, Inc. (ELVN, SEC CIK 1672619) filed its latest 10-K annual report on March 3, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on August 5, 2026 and Form 4 insider filings as recently as October 5, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of June 30, 2026, 27 institutional investment managers tracked by SignalX reported holding Enliven Therapeutics, Inc. (ELVN) shares worth $1.4 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Garland J. Scott on October 1, 2026 of 13,000 shares at $46.67 per share.
- In the last 90 days, ELVN insiders reported 0 open-market purchases ($0) and 22 open-market sales ($11.9M) on Form 4, a net sale of $11.9M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 22 sells
- Net −$11.9M
- 13F holders
- 27 funds
- $1.4B · +2 vs prior quarter
- Latest 8-K
- Aug 5, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: Clinical-stage biopharma developing selective small molecule therapeutics targeting validated biology using precision medicine
- New emphasis on ELVN-001, a selective ATP-competitive BCR-ABL TKI for CML addressing resistance, off-target toxicity, and dosing challenges
- Strategic pivot to prioritize ELVN-001; exploring strategic alternatives for ELVN-002 to focus resources on lead program
- ENABLE Phase 1 trial enrolled 90 patients; 47% cumulative MMR rate by 24 weeks with favorable safety in heavily pretreated CML patients
- CEO Rick Fair joined Dec 2025, bringing 25+ years pharma leadership including commercial launches for $23B oncology portfolio
Risk Factors
- FDA regulatory risk: potential delays or denials if ELVN-001 clinical trial design or data interpretation not accepted, requiring additional clinical studies
- Geopolitical exposure: clinical development reliant on sites in U.S., Europe and China, subject to global trade tensions and tariffs impact
- Supply chain vulnerability: changes in manufacturing process require FDA comparability analysis and approval, possibly delaying clinical trials
- Competitive risk: dependency on ELVN-001 amid high biopharma attrition rates and competing therapies impacting commercial acceptance
- Financial risk: accumulated deficit $347.2M, net loss $103.7M in 2025, need for substantial additional funding to sustain operations
Management Discussion & Analysis
- No revenue generated in FY 2025 or 2024; no expected revenue in foreseeable future
- Net loss $103.7M in 2025 vs $89.0M in 2024; operating expenses $119.7M vs $104.6M; operating margin negative and worsening
- R&D increased to $85.9M in 2025 from $80.8M in 2024; ELVN-001 external costs up $7.8M, ELVN-002 external costs down $12.8M; G&A rose to $33.8M from $23.8M driven by $9.6M higher stock comp
- Cash, cash equivalents and marketable securities $462.6M at December 31, 2025; raised $230M in June 2025 Public Offering, $90M in March 2024 Private Placement, $40M via Sales Agreement through 12/31/2025
- Management expects operating losses and R&D expenses to increase; cash runway covers at least next 12 months; key risks include clinical trial progress, regulatory approval, need for further capital raises, and macroeconomic/geopolitical uncertainties
AI summary of the ELVN 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Revenue $0, unchanged YoY; no product or other revenue generated
- Net loss $32.5M vs $25.3M YoY; operating margin not applicable with zero revenue
- ELVN-001 R&D $8.3M vs $6.0M; ELVN-002 R&D $1.2M vs $3.5M
- Cash, equivalents and marketable securities $895.2M as of June 30, 2026
- $460.0M gross proceeds from June 2026 public offering; funding sufficient for at least 12 months
Risk Factors
- ELVN-002 development discontinued while exploring strategic alternatives, concentrating resources on ELVN-001 and its upcoming pivotal trial
- Clinical-stage regulatory risk: FDA may require bridging studies for alternative ELVN-001 tablet formulations
- ELVN-001 Phase 1 outcomes may fail to support later-stage efficacy or safety requirements
- June 2026 ENABLE data were positive, but no clinical trial has yet been completed
- Net loss $56.1 million and accumulated deficit $403.3 million as of June 30, 2026
AI summary of the ELVN 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 financial results for quarter ended June 30, 2026
- Press release issued August 5, 2026
Item EX-99.1: Item EX-99.1
- Q2 2026 Phase 1 data support ELVN-001 advancement, with 61% overall MMR and 48% MMR by 24 weeks at 80 mg QD
- Earlier-line patients showed 67% overall MMR and 55% MMR by 24 weeks, strengthening the targeted Phase 3 opportunity
Item 7.01: Regulation FD Disclosure
- Reg FD disclosure centers on a planned offering and expected net proceeds
- Offering closing date remains dependent on market conditions and customary closing conditions
Item EX-99.1: Item EX-99.1
- Upsized offering of 8,933,334 shares and pre-funded warrants for 1,733,333 shares priced at $37.50 per share
- Approximately $400.0 million gross proceeds before underwriting discounts and offering expenses, strengthening clinical-development funding
Item 1.01: Entry into a Material Definitive Agreement
- $376.0M net proceeds from sale of 8,933,334 shares at $37.50, strengthening Enliven’s funding position
- Additional 1,733,333 pre-funded warrants create near-term dilution potential at $0.001 exercise price
Item 7.01: Regulation FD Disclosure
- Updated positive Phase 1 ENABLE data for ELVN-001 in chronic myeloid leukemia
- Data announcement dated June 11, 2026, with full results in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Phase 1b efficacy: 61% overall MMR and 48% achieved MMR by 24 weeks at 80 mg QD
- Broader Phase 1b achieved MMR: 67% among patients with 1–2 prior TKIs
Item 8.01: Other Events
- Phase 1 ENABLE enrolled 161 heavily pretreated CML patients; 70% had received at least three prior TKIs
- ELVN-001 achieved 40% MMR in Phase 1b and 48% at the selected 80 mg QD dose by 24 weeks
AI summaries of ELVN 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ELVN
Don't miss the next ELVN filing
- Alerts as it files. A push when ELVN files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ELVN, by share count.
- Ask anything. An AI agent that reads every ELVN filing and answers with sources.
ELVN alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Garland J. Scott | M | Oct 1, 2026 | 13,000 | $15.47 |
| Garland J. Scott | Sell | Oct 1, 2026 | 13,000 | $46.67 |
| Garland J. Scott | M | Oct 1, 2026 | 13,000 | - |
| Hohl Benjamin | Sell | Sep 17, 2026 | 2,194 | $50.72 |
| Hohl Benjamin | M | Sep 17, 2026 | 3,982 | $14.85 |
| Hohl Benjamin | Sell | Sep 17, 2026 | 3,535 | $50.03 |
| Collins Helen Louise | Sell | Sep 17, 2026 | 1,844 | $50.71 |
| Hohl Benjamin | M | Sep 17, 2026 | 3,982 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Operating Income | -$83.5M | -$104.6M | -$119.7M | |
| Net Income | -$71.6M | -$89.0M | -$103.7M | |
| Balance Sheet | ||||
| Total Assets | $271.9M | $325.8M | $476.2M | |
| Equity | $245.9M | $309.8M | $459.6M | |
| ROE | -29.1% | -28.7% | -22.6% | |
| Per Share | ||||
| EPS | $-2.01 | $-1.89 | $-1.83 | |
| Cash Flow | ||||
| Operating CF | -$61.3M | -$73.2M | -$70.3M | |
Source: XBRL data in Enliven Therapeutics, Inc. (ELVN)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate ELVN share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 27 | $1.39B |
| Q1 2026 | 25 | $747.3M |
| Q4 2025 | 21 | $292.6M |
| Q3 2025 | 23 | $393.0M |
| Q2 2025 | 22 | $379.5M |
| Q1 2025 | 17 | $241.0M |
| Q4 2024 | 13 | $269.1M |
| Q3 2024 | 10 | $85.4M |
- FMR LLC (Fidelity)+3.20M (+47%)
- T. Rowe Price Group+2.81M (+2871%)
- BlackRock+675.0K (+18%)
- Vanguard Capital Management LLC+400.8K (+18%)
- Citadel Advisors LLC+325.1K (+19%)
- Goldman Sachs Group−151.0K (-32%)
- Prudential Financial−49.4K (-74%)
- Dimensional Fund Advisors−10.3K (-2%)
- Morgan Stanley−8.6K (-2%)
- BNY Mellon−1.2K (-1%)
- Blackstone Group+215.7K
- Two Sigma Investments+22.8K
- Fifth Third Bancorp+4
- Raymond James Financial−10.6K
Source: 13F-HR filings on SEC EDGAR (aggregated from 158 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ELVN filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Sep 21, 2026 | - | - | - |
| 4 | Sep 21, 2026 | - | - | - |
| 4 | Aug 19, 2026 | - | - | - |
| 4 | Aug 19, 2026 | - | - | - |
| 4 | Aug 6, 2026 | - | - | - |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 4 | Jul 21, 2026 | - | - | - |
| 4 | Jul 21, 2026 | - | - | - |
| 4 | Jul 8, 2026 | - | - | - |
| 4 | Jun 24, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 8-K | Jun 12, 2026 | - | Analysis | - |
| 8-K | Jun 11, 2026 | - | Analysis | - |
| 8-K | Jun 10, 2026 | - | Analysis | |
| 4 | Jun 9, 2026 | - | - | |
| 4 | May 20, 2026 | - | - | |
| 8-K | May 7, 2026 | - | Analysis | |
| 10-Q | May 7, 2026 | Mar 31, 2026 | Analysis | |
| 4 | Apr 21, 2026 | - | - | - |
| 4 | Mar 27, 2026 | - | - | - |
| 4 | Mar 19, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
ELVN SEC filings: frequently asked questions
Are ELVN insiders buying or selling?
In the last 90 days, Enliven Therapeutics, Inc. (ELVN) officers, directors and 10% owners reported no open-market purchases and 22 open-market sales worth $11.9 million by 4 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold ELVN stock?
As of June 30, 2026, the largest Enliven Therapeutics, Inc. (ELVN) holders among the 13F filers tracked by SignalX were FMR LLC (Fidelity) ($508.8 million), BlackRock ($221.3 million), T. Rowe Price Group ($147.4 million), Vanguard Capital Management LLC ($130.4 million), Citadel Advisors LLC ($105.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What are the main risks in ELVN's latest 10-K?
In the 10-K filed March 3, 2026, Enliven Therapeutics, Inc. (ELVN) flagged: FDA regulatory risk: potential delays or denials if ELVN-001 clinical trial design or data interpretation not accepted, requiring additional clinical studies. Geopolitical exposure: clinical development reliant on sites in U.S., Europe and China, subject to global trade tensions and tariffs impact. (AI summary of the Risk Factors section.)
What did ELVN report in its latest 8-K?
Enliven Therapeutics, Inc. (ELVN) filed an 8-K on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q2 2026 financial results for quarter ended June 30, 2026.
What are the latest ELVN SEC filings?
Enliven Therapeutics, Inc. (ELVN) filed its latest 10-K annual report on March 3, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on August 5, 2026 and a Form 4 insider filing on October 5, 2026.
What is ELVN's SEC CIK number?
Enliven Therapeutics, Inc. (ELVN)'s SEC Central Index Key (CIK) is 1672619. EDGAR lists every ELVN filing under that number.
Ask anything about ELVN
The research agent reads ELVN's filings, financials, insider trades and 13F holders, then answers with sources.